07.09.2022 - BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) - Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ... Seite 1

Related Keywords

Boston , Massachusetts , United States , Marcio Souza , Praxis Precision Medicines Inc , Drug Administration , Nasdaq , Precision Medicines , Investigational New Drug ,